Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

被引:120
作者
Tonolo, G
Melis, MG
Formato, M
Angius, MF
Carboni, A
Brizzi, P
Ciccarese, M
Cherchi, GM
Maioli, M
机构
[1] Univ Sassari, Ist Clin Med, Chair Metab Dis, I-07100 Sassari, Italy
[2] Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy
关键词
glycosaminoglycans; metabolic syndrome; microalbuminuria; NIDDM;
D O I
10.1046/j.1365-2362.2000.00735.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Experimental evidence indicates that statins might have direct vascular effects independently from low-density lipoprotein (LDL) cholesterol reduction and we reported that the reduction in urinary albumin excretion rate during Simvastatin treatment in type 2 diabetic patients was not correlated with LDL-cholesterol decrease. However in humans there are no data regarding possible additional effects of Simvastatin on blood pressure and urinary albumin excretion beyond its capacity to lower serum cholesterol. Patients and methods Twenty-six microalbuminuric hypertensive type 2 diabetic patients (diastolic blood pressure - after four months wash-out from the previous antihypertensive therapy - consistently > 90 and < 100 mmHg; plasma LDL-cholesterol > 3.9 and < 6.5 mmol L-1) were enrolled in the study. In random order, these patients received Simvastatin (20 mg day(-1)) or Cholestyramine (6 g three times a day) for a period of 10 months and after three months of wash-out (cross-over) the sequence was reversed for an additional 10 months. Blood pressure, lipid parameters, glycated haemoglobin and urinary albumin excretion were measured during the study. Additionally, in eight patients, urinary glycosaminoglycan excretion (GAG) was also measured during the study. Results Simvastatin and Cholestyramine were equally effective in reducing total and LDL cholesterol. Only during Simvastatin treatment a significant reduction in diastolic blood pressure and both 24 h urinary albumin and GAG excretion rates were observed, while no significant changes were seen with Cholestyramine treatment. Conclusions Our results clearly show for the first time that the reduction of blood pressure, together with 24 h urinary albumin excretion rate - two established cardiovascular risk factors, obtained during Simvastatin therapy in hypertensive type 2 diabetic patients - is in large part independent from the reduction of LDL Cholesterol.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 49 条
  • [1] Beyond lipids - the role of the endothelium in coronary artery disease
    Aengevaeren, WR
    [J]. ATHEROSCLEROSIS, 1999, 147 : S11 - S16
  • [2] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION
    ANDERSON, TJ
    MEREDITH, IT
    YEUNG, AC
    FREI, B
    SELWYN, AP
    GANZ, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) : 488 - 493
  • [3] AULIFFE AV, 1996, DIABETIC MED, V13, P758
  • [4] Direct vascular effects of HMG-CoA reductase inhibitors
    Bellosta, S
    Bernini, F
    Ferri, N
    Quarato, P
    Canavesi, M
    Arnaboldi, L
    Fumagalli, R
    Paoletti, R
    Corsini, A
    [J]. ATHEROSCLEROSIS, 1998, 137 : S101 - S109
  • [5] A MODIFIED URONIC ACID CARBAZOLE REACTION
    BITTER, T
    MUIR, HM
    [J]. ANALYTICAL BIOCHEMISTRY, 1962, 4 (04) : 330 - &
  • [6] EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH)
    BUCHWALD, H
    VARCO, RL
    MATTS, JP
    LONG, JM
    FITCH, LL
    CAMPBELL, GS
    PEARCE, MB
    YELLIN, AE
    EDMISTON, WA
    SMINK, RD
    SAWIN, HS
    CAMPOS, CT
    HANSEN, BJ
    TUNA, N
    KARNEGIS, JN
    SANMARCO, ME
    AMPLATZ, K
    CASTANEDAZUNIGA, WR
    HUNTER, DW
    BISSETT, JK
    WEBER, FJ
    STEVENSON, JW
    LEON, AS
    CHALMERS, TC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) : 946 - 955
  • [7] BULPITT CJ, 1979, LANCET, V2, P134
  • [8] NEW ELECTROPHORETIC METHOD FOR THE COMPLETE SEPARATION OF ALL KNOWN ANIMAL GLYCOSAMINOGLYCANS IN A MONODIMENSIONAL RUN
    CAPPELLETTI, R
    DELROSSO, M
    CHIARUGI, VP
    [J]. ANALYTICAL BIOCHEMISTRY, 1979, 99 (02) : 311 - 315
  • [9] MODIFICATIONS OF LOW-DENSITY-LIPOPROTEIN INDUCED BY THE INTERACTION WITH HUMAN PLASMA GLYCOSAMINOGLYCAN PROTEIN COMPLEXES
    CHERCHI, GM
    FORMATO, M
    DEMURO, P
    MASSERINI, M
    VARANI, I
    DELUCA, G
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1994, 1212 (03): : 345 - 352
  • [10] Cox DA, 1996, PHARMACOL REV, V48, P3